Page last updated: 2024-12-06

datelliptium chloride

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

detalliptinium: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID72034
CHEMBL ID68332
SCHEMBL ID2734605
MeSH IDM0166993

Synonyms (31)

Synonym
datelliptium chloride ,
detalliptinium
sr-95156b
nsc311152 ,
nsc-311152
CHEMBL68332
unii-v5qkf7q20o
2-(2-(diethylamino)ethyl)-9-hydroxy-5,11-dimethyl-6h-pyrido(4,3-b)carbazolium chloride
cloruro de dateliptio
datelliptii chloridum
datelliptium chloride [inn]
datelliptii chloridum [latin]
105118-14-7
chlorure de datelliptium
cloruro de dateliptio [spanish]
chlorure de datelliptium [french]
n-2-(diethylaminoethyl)-9-hydroxyellipticinum chloride
v5qkf7q20o ,
datelliptium
SCHEMBL2734605
HY-U00337
datelliptium (chloride)
CS-7369
BCP32779
Q27291564
2-[2-(diethylamino)ethyl]-5,11-dimethyl-6h-pyrido[4,3-b]carbazol-2-ium-9-ol;chloride
EX-A4212
MS-26725
105118-14-7 (chloride)
AC-35683
AKOS040759136
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (23)

Assay IDTitleYearJournalArticle
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID231710Ratio between brain tumor full panel [A] and sub panel [B]1994Journal of medicinal chemistry, Jul-08, Volume: 37, Issue:14
Anticancer specificity of some ellipticinium salts against human brain tumors in vitro.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID90126Concentration yielding an amount of cellular protein at the end of the incubation that is the same as at the beginning of the incubation in full panel1994Journal of medicinal chemistry, Jul-08, Volume: 37, Issue:14
Anticancer specificity of some ellipticinium salts against human brain tumors in vitro.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID90125Concentration yielding an amount of cellular protein at the end of the incubation that is the same as at the beginning of the incubation in brain tumor sub panel1994Journal of medicinal chemistry, Jul-08, Volume: 37, Issue:14
Anticancer specificity of some ellipticinium salts against human brain tumors in vitro.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID235001TGI correlation coefficient value of the compound1994Journal of medicinal chemistry, Jul-08, Volume: 37, Issue:14
Anticancer specificity of some ellipticinium salts against human brain tumors in vitro.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (28.57)18.7374
1990's4 (57.14)18.2507
2000's0 (0.00)29.6817
2010's1 (14.29)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.21

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.21 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.21)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (12.50%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (87.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]